EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Rudolf Buchheim Award 2026: solanidine as a dietary derived CYP2D6 biomarker

Julian Peter Müller

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-05650-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Julian Peter Müller. Beteiligte Einrichtung: Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Wendlingweg 2, 52074, Aachen, Germany. jumueller@ukaachen.de. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Awards and Prizes. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum RWTH Aachen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) is annually awarding the Rudolf Buchheim Award. This year the Rudolf Buchheim Award was awarded to Julian Peter Müller for outstanding work of a young researcher in the field of clinical pharmacology. He investigated the performance and applicability of the novel CYP2D6 biomarker solanidine. CYP2D6 is a genotypic and phenotypic highly variable drug-metabolizing enzyme involved in the metabolism of about 20% of commonly used drugs. Variability in CYP2D6 activity may lead to pronounced interindividual deviations in the pharmacokinetics of its drug substrates, potentially leading to adverse events or therapy failure. CYP2D6 genotyping allows to predict metabolizer phenotypes, e.g., poor, intermediate, normal or ultrarapid, but cannot take into account additional variation due to co-medication or other factors. In the awarded work he could demonstrate that a single plasma sample is sufficient for accurate CYP2D6 phenotyping, and that by using solanidine, CYP2D6 phenoconversion, a genotype–phenotype mismatch, due to polypharmacy can be elucidated. The use of the CYP2D6 biomarker solanidine allows to study non-genetic variation of CYP2D6 activity and opens up new possibilities in personalized medicine. Application of solanidine phenotyping may help to understand factors of CYP2D6 phenoconversion and may be applied with patients to optimize therapy decisions and to improve outcomes and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2D6Awards and PrizesHumansBiomarkersPhenotype

Stichwörter der Autor:innen

BiomarkerCYP2D6Drug metabolismPersonalized medicinePhenoconversionSolanidine

Substanzen

Cytochrome P-450 CYP2D6Biomarkers

Autor:innen und Institutionen

  • Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Wendlingweg 2, 52074, Aachen, Germany. jumueller@ukaachen.de.

Förderung

  • Universitätsklinikum RWTH Aachen

Zitieren

APA

Müller, J. P. (2026). Rudolf Buchheim Award 2026: solanidine as a dietary derived CYP2D6 biomarker. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05650-w

Vancouver

Müller JP. Rudolf Buchheim Award 2026: solanidine as a dietary derived CYP2D6 biomarker. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05650-w

BibTeX
@article{Mller2026,
  author = {Müller, Julian Peter},
  title = {Rudolf Buchheim Award 2026: solanidine as a dietary derived CYP2D6 biomarker},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-05650-w}
}
Kostenlos starten →